文献速递肿瘤 PET/CT神经核医学核素与放射性配体治疗

在嗜铬细胞瘤和副神经节瘤患者队列中头对头比较[68Ga]Ga-DOTA-NOC与[18F]DOPA PET/CT

Head-to-head comparison between [68Ga]Ga-DOTA-NOC and [18F]DOPA PET/CT in a diverse cohort of patients with pheochromocytomas and paragangliomas.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2024-02-01

回顾性纳入85例经组织病理学确诊的嗜铬细胞瘤和副神经节瘤(PPGLs)患者,均行[68Ga]Ga-DOTA-NOC与[18F]DOPA PET/CT。患者水平检出率分别为87.1%(74/85)与89.4%(76/85),差异无统计学意义(p=0.634);病灶水平检出率分别为80.8%(479/593)与71.2%(422/593),差异有统计学意义(p<0.001)。[68Ga]Ga-DOTA-NOC在交感副神经节瘤转移灶和SDHx相关肿瘤中检出更高,[18F]DOPA在嗜铬细胞瘤原发/复发及转移灶中检出更高;作者认为两者在合适临床情境下互补。

要点

  • 患者水平检出率两种示踪剂无显著差异(87.1% vs 89.4%,p=0.634)。
  • 病灶水平[68Ga]Ga-DOTA-NOC检出率高于[18F]DOPA(80.8% vs 71.2%,p<0.001)。
  • 作者认为[68Ga]Ga-DOTA-NOC可考虑作为sPGL转移灶和SDHx相关肿瘤的一线示踪剂。

核心结论

  • 作者认为[68Ga]Ga-DOTA-NOC与[18F]DOPA在合适临床情境下诊断PPGL具有互补性。
  • 作者认为[68Ga]Ga-DOTA-NOC应被考虑作为检测交感副神经节瘤(sPGL)转移灶和SDHx相关肿瘤的理想一线示踪剂。
  • 作者认为[18F]DOPA可能是评估非SDHx相关嗜铬细胞瘤(PCC)的最佳示踪剂,尤其用于检测原发病灶和监测复发。

研究设计与样本

  • 回顾性研究纳入2017年3月至2023年6月期间接受[68Ga]Ga-DOTA-NOC与[18F]DOPA PET/CT两种检查的85例组织病理学确诊PPGLs患者。
  • 患者中男性48例,年龄43岁±17(标准差)。
  • PPGLs分为嗜铬细胞瘤(PCC)、交感副神经节瘤(sPGL)和头颈部副神经节瘤(HNPGL)进行对比分析。
  • 检出率按患者水平和病灶水平分析,采用卡方检验/Fisher精确检验比较。

主要发现

  • 患者水平检出率[68Ga]Ga-DOTA-NOC为87.1%(74/85)vs [18F]DOPA为89.4%(76/85),p=0.634。
  • 病灶水平检出率[68Ga]Ga-DOTA-NOC为80.8%(479/593)vs [18F]DOPA为71.2%(422/593),p<0.001。
  • 1例复发性PCC患者双阴性显像,66例患者双阳性显像,10例为[68Ga]Ga-DOTA-NOC阴性/[18F]DOPA阳性,8例为[68Ga]Ga-DOTA-NOC阳性/[18F]DOPA阴性。
  • sPGL转移灶检出率[68Ga]Ga-DOTA-NOC为91.1%(236/259)vs [18F]DOPA为48.6%(126/259),p<0.001;SDHx相关PPGL检出率[68Ga]Ga-DOTA-NOC为89.6%(86/96)vs [18F]DOPA为50.0%(48/96),p<0.001。
  • PCC原发/复发灶检出率[18F]DOPA为94.3%(50/53)vs [68Ga]Ga-DOTA-NOC为62.3%(33/53),p<0.001;PCC转移灶检出率[18F]DOPA为87.9%(174/198)vs [68Ga]Ga-DOTA-NOC为69.2%(137/198),p<0.001。

临床怎么用

  • 作者认为[68Ga]Ga-DOTA-NOC应被考虑作为检测sPGL转移灶和SDHx相关肿瘤的理想一线示踪剂。
  • 作者认为[18F]DOPA可能是评估非SDHx相关PCC的最佳示踪剂,尤其用于检测原发病灶和监测复发。
  • 作者认为两种示踪剂在合适临床情境下诊断PPGL具有互补性。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To compare the detection ability of 68Ga-labelled DOTA-l-Nal3-octreotide ([68Ga]Ga-DOTA-NOC) and 6-[18F]fluoro-L-3,4-dihydroxyphenylalanine ([18F]DOPA) in patients with phaeochromocytomas and paragangliomas (PPGLs) of different origins and gene mutations, such as germline succinate dehydrogenase complex genes (SDHx). METHODS: Eighty-five patients with histopathologically confirmed PPGLs who underwent both [68Ga]Ga-DOTA-NOC and [18F]DOPA PET/CT from March 2017 to June 2023 were enrolled in this retrospective study. For comparative analyses, PPGLs were classified as phaeochromocytoma (PCC), sympathetic paraganglioma (sPGL), and head/neck paraganglioma (HNPGL). Detection rates were analyzed on per-patient and per-lesion bases and compared using the Chi-square/Fischer's exact test. RESULTS: Among 85 patients with PPGLs (48 males; 43 years ± 17 [SD]), the patient-based detection rates of [68Ga]Ga-DOTA-NOC and [18F]DOPA PET/CT were 87.1% (74/85) and 89.4% (76/85), respectively (p = 0.634), and the lesion-based detection rates were 80.8% (479/593) and 71.2% (422/593), respectively (p < 0.001). Only one patient with a recurrent PCC presented double-negative imaging, while 66 patients exhibited double-positive imaging. The remaining patients were either [68Ga]Ga-DOTA-NOC-negative/[18F]DOPA-positive (n = 10) or [68Ga]Ga-DOTA-NOC-positive/[18F]DOPA-negative (n = 8). In subgroup analyses, [68Ga]Ga-DOTA-NOC PET/CT detected significantly more metastases of sPGL (91.1%, 236/259) and SDHx-related PPGL (89.6%, 86/96) than [18F]DOPA PET/CT (48.6%[126/259] and 50.0%[48/96], respectively; both p < 0.001). However, [18F]DOPA showed significantly higher detection rates of PCC in both primary/recurrent and metastatic lesions (94.3%[50/53] vs. 62.3%[33/53] and 87.9%[174/198] vs. 69.2%[137/198], respectively; both p < 0.001). Regarding metastases in different organs, [68Ga]Ga-DOTA-NOC PET/CT detected more lesions than [18F]DOPA PET/CT in bone (96.2%[176/183] vs. 66.1%[121/183]; p < 0.001) and lymph nodes (82.0%[73/89] vs. 53.9%[48/89]; p < 0.001) but less lesions in peritoneum (20%[4/20] vs. 100%[20/20]; p < 0.001). CONCLUSION: [68Ga]Ga-DOTA-NOC and [18F]DOPA are complementary in diagnosing PPGL under the appropriate clinical setting. [68Ga]Ga-DOTA-NOC should be considered as the ideal first-line tracer for detecting metastases of sPGL and SDHx-related tumours, whereas [18F]DOPA may be the optimal tracer for evaluating non-SDHx-related PCC, especially in detecting primary lesions and monitoring recurrence.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. He Q, Zhang Z, Zhang L, et al. Head-to-head comparison between [68Ga]Ga-DOTA-NOC and [18F]DOPA PET/CT in a diverse cohort of patients with pheochromocytomas and paragangliomas. Eur J Nucl Med Mol Imaging. 2024. PMID: 38300262. doi:10.1007/s00259-024-06622-z

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。